Patents by Inventor Goncalo Abecasis

Goncalo Abecasis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment Of Macular Degeneration With Complement Factor D (CFD) Inhibitors
    Publication number: 20250129371
    Abstract: The present disclosure generally relates to the treatment of subjects having macular degeneration or at risk of developing macular degeneration by administering a Complement Factor D (CFD) inhibitor to the subject, and to methods of identifying subjects having an increased risk of developing macular degeneration.
    Type: Application
    Filed: October 10, 2024
    Publication date: April 24, 2025
    Inventors: Neelroop Parikshak, Eric Jorgenson, Xinyuan Zhang, Giovanni Coppola, Goncalo Abecasis, Aris Baras, Botir Sagdullaev, Ying Hu, Kevin Kanning, Aarin Jones, Huy Vu
  • Genome-based methods for reducing cardiovascular risk
    Patent number: 12264366
    Abstract: The present disclosure provides methods of reducing cardiovascular risk by administration of a PCSK9 inhibitor to patients having a genetic profile associated with response to PCSK9 inhibitor therapy.
    Type: Grant
    Filed: May 16, 2020
    Date of Patent: April 1, 2025
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Amy Damask, Charles Paulding, Aris Baras, Goncalo Abecasis
  • Kelch domain containing 7B (KLHDC7B) variants and uses thereof
    Patent number: 12258627
    Abstract: The present disclosure provides methods of treating subjects having hearing loss, methods of identifying subjects having an increased risk of developing hearing loss, and methods of detecting Kelch Domain Containing 7B (KLHDC7B) variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: April 19, 2023
    Date of Patent: March 25, 2025
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Aris Baras, Meghan Drummond Samuelson, Goncalo Abecasis
  • Methods Of Treating Skin Cancer With Carboxypeptidase Vitellogenic Like (CPVL) Inhibitors
    Publication number: 20250017929
    Abstract: The present disclosure provides methods of treating a subject having skin cancer or preventing a subject from developing skin cancer, and methods of identifying subjects having an increased risk of developing skin cancer.
    Type: Application
    Filed: July 17, 2024
    Publication date: January 16, 2025
    Inventors: Xinyuan Zhang, Julie Horowitz, Stefan Semrau, Goncalo Abecasis, Gavin Thurston, Eric Jorgenson, Aris Baras
  • Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonists
    Patent number: 12186378
    Abstract: The present disclosure provides methods of treating subjects having skin cancer or at risk of developing skin cancer, and methods of identifying subjects having an increased risk of developing skin cancer.
    Type: Grant
    Filed: July 5, 2022
    Date of Patent: January 7, 2025
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Manuel Allen Revez Ferreira, Joshua Backman, Alexander Li, Michael Kessler, Eric Jorgenson, Aris Baras, Goncalo Abecasis
  • Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors
    Patent number: 12070460
    Abstract: The present disclosure provides methods of treating a subject having skin cancer or preventing a subject from developing skin cancer, and methods of identifying subjects having an increased risk of developing skin cancer.
    Type: Grant
    Filed: July 5, 2022
    Date of Patent: August 27, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Xinyuan Zhang, Julie Horowitz, Stefan Semrau, Goncalo Abecasis, Gavin Thurston, Eric Jorgenson, Aris Baras
  • Treatment Of Inflammation With Glucocorticoids And Angiopoietin-Like 7 (ANGPTL7) Inhibitors
    Publication number: 20240148774
    Abstract: The present disclosure provides methods of treating subjects having inflammation with an Angiopoietin-Like 7 (ANGPTL7) inhibitor and a glucocorticoid, methods of decreasing glucocorticoid-induced ophthalmic conditions in subjects, and methods of identifying subjects having an increased risk of developing glucocorticoid-induced ophthalmic conditions.
    Type: Application
    Filed: November 16, 2023
    Publication date: May 9, 2024
    Inventors: Gaurang Patel, Ying Hu, Kavita Praveen, Giovanni Coppola, Goncalo Abecasis, Aris Baras, Carmelo Romano
  • Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) Inhibitors
    Publication number: 20240102013
    Abstract: The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human Son of Sevenless 2 (SOS2) variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: October 12, 2023
    Publication date: March 28, 2024
    Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Goncalo Abecasis, Aris Baras
  • Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors
    Patent number: 11865134
    Abstract: The present disclosure provides methods of treating subjects having inflammation with an Angiopoietin-Like 7 (ANGPTL7) inhibitor and a glucocorticoid, methods of decreasing glucocorticoid-induced ophthalmic conditions in subjects, and methods of identifying subjects having an increased risk of developing glucocorticoid-induced ophthalmic conditions.
    Type: Grant
    Filed: February 23, 2022
    Date of Patent: January 9, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gaurang Patel, Ying Hu, Kavita Praveen, Giovanni Coppola, Goncalo Abecasis, Aris Baras, Carmelo Romano
  • Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
    Patent number: 11845989
    Abstract: The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human angiopoietin like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: December 19, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kavita Praveen, Claudia Schurmann, Lauren Gurski, Tanya Teslovich Dostal, Goncalo Abecasis, Aris Baras, Giovanni Coppola, Gaurang Patel, Ying Hu, Carmelo Romano, Giusy Della Gatta, Trikaldarshi Persaud
  • Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors
    Patent number: 11820982
    Abstract: The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human Son of Sevenless 2 (SOS2) variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: November 21, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Goncalo Abecasis, Aris Baras
  • Kelch Domain Containing 7B (KLHDC7B) Variants And Uses Thereof
    Publication number: 20230366024
    Abstract: The present disclosure provides methods of treating subjects having hearing loss, methods of identifying subjects having an increased risk of developing hearing loss, and methods of detecting Kelch Domain Containing 7B (KLHDC7B) variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: April 19, 2023
    Publication date: November 16, 2023
    Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Aris Baras, Meghan Drummond Samuelson, Goncalo Abecasis
  • Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
    Patent number: 11767526
    Abstract: The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human angiopoietin like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: September 26, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kavita Praveen, Claudia Schurmann, Lauren Gurski, Tanya Teslovich Dostal, Goncalo Abecasis, Aris Baras, Giovanni Coppola, Carmelo Romano
  • Treatment Of Lung Conditions With Integrin Subunit Alpha 1 (ITGA1) Inhibitors
    Publication number: 20230192864
    Abstract: The present disclosure provides methods of treating subjects having a lung disease such as a fibrotic lung disease, pulmonary fibrosis, interstitial lung disease, chronic obstructive pulmonary disease (COPD), or asthma, or at risk of developing a lung disease, and methods of identifying subjects having an increased risk of developing a lung disease.
    Type: Application
    Filed: December 16, 2022
    Publication date: June 22, 2023
    Inventors: Manuel Allen Revez Ferreira, Julie E. Horowitz, Katherine Siminovitch, Goncalo Abecasis, Aris Baras, Maria Cristina Suciu
  • Kelch domain containing 7B (KLHDC7B) variants and uses thereof
    Patent number: 11674177
    Abstract: The present disclosure provides methods of treating subjects having hearing loss, methods of identifying subjects having an increased risk of developing hearing loss, and methods of detecting Kelch Domain Containing 7B (KLHDC7B) variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: June 13, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Aris Baras, Meghan Drummond Samuelson, Goncalo Abecasis
  • Treatment Of Inflammatory Diseases With RAS Protein Activator Like 3 (RASAL3) Inhibitors
    Publication number: 20230074721
    Abstract: The present disclosure provides methods of treating subjects having an inflammatory disease, and methods of identifying subjects having an increased risk of developing an inflammatory disease.
    Type: Application
    Filed: August 24, 2022
    Publication date: March 9, 2023
    Inventors: Manuel Allen Revez Ferreira, Joshua Backman, Alexander Li, Lauren Gurski, Julie E. Horowitz, Katherine Siminovitch, Goncalo Abecasis, Aris Baras
  • Methods Of Treating Skin Cancer With Carboxypeptidase Vitellogenic Like (CPVL) Inhibitors
    Publication number: 20230037524
    Abstract: The present disclosure provides methods of treating a subject having skin cancer or preventing a subject from developing skin cancer, and methods of identifying subjects having an increased risk of developing skin cancer.
    Type: Application
    Filed: July 5, 2022
    Publication date: February 9, 2023
    Inventors: Xinyuan Zhang, Julie Horowitz, Stefan Semrau, Goncalo Abecasis, Gavin Thurston, Eric Jorgenson, Aris Baras
  • Treatment of Varicose Veins With Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) Agonists
    Publication number: 20230041060
    Abstract: The present disclosure provides methods of treating subjects having varicose veins or at risk of developing varicose veins, methods of identifying subjects having an increased risk of developing varicose veins, and methods of detecting Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: July 5, 2022
    Publication date: February 9, 2023
    Inventors: Manuel Allen Revez Ferreira, Joshua Backman, Alexander Li, Aris Baras, Goncalo Abecasis
  • Treatment Of Cognitive Impairment With Alpha-N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 5 (ST6GALNAC5) Inhibitors
    Publication number: 20230034093
    Abstract: The present disclosure provides methods of treating subjects having cognitive impairment or at risk of developing cognitive impairment, and methods of identifying subjects having an increased risk of developing cognitive impairment.
    Type: Application
    Filed: June 30, 2022
    Publication date: February 2, 2023
    Inventors: Jonathan Marchini, Manuel Allen Revez Ferreira, Giovanni Coppola, Goncalo Abecasis, Aris Baras
  • Methods Of Treating A Metabolic Disorder With Mitogen-Activated Protein Kinase Kinase Kinase 15 (MAP3K15) Inhibitors
    Publication number: 20230025878
    Abstract: The present disclosure provides methods of treating a subject having a metabolic disorder or is at risk of developing a metabolic disorder or preventing a subject from developing a metabolic disorder, and methods of identifying subjects having an increased risk of developing a metabolic disorder.
    Type: Application
    Filed: June 30, 2022
    Publication date: January 26, 2023
    Inventors: Manuel Allen Revez Ferreira, Joshua Backman, Alexander Li, Luca Andrea Lotta, Goncalo Abecasis, Aris Baras